Evaluation of the effects of montelukast, mometasone furoate, and combined therapyon adenoid size: a randomized, prospective, clinical trial with objective data

Birgül TUHANİOĞLU; Sanem Okşan ERKAN

Makale detayları

Evaluation of the effects of montelukast, mometasone furoate, and combined therapyon adenoid size: a randomized, prospective, clinical trial with objective data

Yazarlar:

Birgül TUHANİOĞLU | Sanem Okşan ERKAN

Yayıncı:

TUBITAK

Ana Başlıklar:

Sağlık teşvikleri

Dergi:

Turkish Journal of Medical Sciences 2017 Vol.47 Issue 6, pp.1736-1743

Belge Tipi:

Makale

Yayın Tarihi:

11/2017

Belge Dili:

İngilizce

Document ID (Org No.):

2000750982

Sıklık:

İki Aylık

eISSN:

1303-6165

pISSN:

1300-0144

Özet:

 

Background/aim: The incidence of adenoid hypertrophy is 2%-3% in children. Adenoidectomy is a commonly performed procedure in children that may cause complications such as early or late bleeding (4%-5%), recurrence of adenoid tissue (10%-20%), and postoperative respiratory problems (27%). Therefore, medical therapy alternatives to adenoidectomy are important and must be tried before surgery. In this study, we investigated the efficacy of mometasone furoate, montelukast, and a combination of these drugs in pediatric patients with adenoid hypertrophy who were scheduled for reduction with medical therapy after not being recommended for surgery.Materials and methods: The study included 120 children with adenoid hypertrophy aged between 4 and 10 years. The patients were randomized into 4 separate groups, with 30 in each group. Group 1 received 100 μg of mometasone furoate per day, group 2 received 4/5 mg (for age) montelukast per day, and group 3 received mometasone furoate + montelukast. Medical therapy continued for 3 months in the treatment groups. Group 4, which comprised patients with mild symptoms, received no treatment and was the control group. The pre- and posttreatment adenoid tissue ratios in lateral neck radiographs were recorded in the four groups. Results: When radiologic measurements of adenoid-to-air passage were calculated, an improvement of 21.76% was observed in group 1 after treatment. The rate of improvement was 22.51% in group 2. There was a 21.79% reduction in adenoid size in group 3 after 3 months? treatment and 12.46% in the control group. There were statistically significant differences between pre- and posttreatment values in every single group administered corticosteroids, montelukast, and combined therapy (P < 0.05).Conclusion: According to our results, both montelukast and mometasone furoate therapies were similarly successful in treating adenoid hypertrophy. Combined therapy has no superiority over single-therapy treatment.

Makale detayları

Evaluation of the effects of montelukast, mometasone furoate, and combined therapyon adenoid size: a randomized, prospective, clinical trial with objective data

Yazarlar: Birgül TUHANİOĞLU | Sanem Okşan ERKAN

Yayıncı: TUBITAK

Ana Başlıklar: Sağlık teşvikleri

Dergi: Turkish Journal of Medical Sciences 2017 Vol.47 Issue 6, pp.1736-1743

Belge Tipi: Makale

Yayın Tarihi: 11/2017

Belge Dili: İngilizce

Document ID (Org No.): 2000750982

Sıklık: İki Aylık

eISSN: 1303-6165

pISSN: 1300-0144

Sayı

Yazarlar:

Birgül TUHANİOĞLU | Sanem Okşan ERKAN

Yayıncı:

TUBITAK

Ana Başlıklar:

Sağlık teşvikleri

Dergi:

Turkish Journal of Medical Sciences 2017 Vol.47 Issue 6, pp.1736-1743

Belge Tipi:

Makale

Yayın Tarihi:

11/2017

Belge Dili:

İngilizce

Document ID (Org No.):

2000750982

Sıklık:

İki Aylık

eISSN:

1303-6165

pISSN:

1300-0144